Abstracts Archive - Page 1201 of 2425 - ACR Meeting Abstracts

Abstract Number: 2948 • 2018 ACR/ARHP Annual Meeting
Deconstructing the in Situ Myeloid Cell Microenvironment in Human Lupus Nephritis Tissue
Paul Hoover^1,2, Tony Jones², Cianna Leatherwood³, Sushrut Waikar⁴, Karen Costenbader³ and Nir Hacohen⁵, ¹Division of Rheumatology, Allergy, Immunology, Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Renal, Brigham and Women's Hospital, Boston, MA, ⁵Harvard Medical School, Boston, MA
Background/Purpose: The cell-types and pathways driving lupus nephritis (LN) are incompletely understood. The Accelerating Medicine Partnership lupus network Pathway Exploration and Analysis in RenaL disease…
Abstract Number: 2949 • 2018 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a heterogeneous clinical presentation and periods of waxing and waning disease. Heterogeneity in SLE is…
Abstract Number: 2950 • 2018 ACR/ARHP Annual Meeting
10X Genomics-Based Single-Cell RNA-Seq Analysis Identifies a Transcriptional Landscape of Inflammation and Fibrosis in Lupus Nephritis
Hemant Suryawanshi¹, Evan Der², Pavel Morozov¹, Robert M. Clancy³, Beatrice Goilav⁴, H. Michael Belmont³, Peter M. Izmirly⁵, Nicole Bornkamp⁶, Nicole Jordan⁷, Ming Wu³, Judith A. James⁸, Joel M. Guthridge⁹, Soumya Raychaudhuri¹⁰, Jill P. Buyon³, Chaim Putterman² and Thomas Tuschl¹, ¹Howard Hughes Medical Institute and The Rockefeller University, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³NYU School of Medicine, New York, NY, ⁴Division of Nephrology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY, ⁶Medicine, NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Harvard Medical School, Boston, MA
Background/Purpose: Renal histology remains a primary tool for classification and treatment decisions in lupus nephritis (LN). Single-cell RNA-seq (scRNA-seq) analysis may provide mechanistic insights into…
Abstract Number: 2951 • 2018 ACR/ARHP Annual Meeting
Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
Jarrat Jordan¹, Kristen Sweet², Matteo Cesaroni¹, Keying Ma², Carol Franks², Loqmane Seridi², Jessica Schreiter³, Robert Gordon², Peter E. Lipsky⁴, Shawn Rose², Frédéric Baribaud², Matthew Loza² and Kim Campbell², ¹Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: We previously reported that treatment with ustekinumab (UST), an anti-IL-12/23 p40 neutralizing monoclonal antibody, improved global and organ-specific measures of disease activity in a…
Abstract Number: 2952 • 2018 ACR/ARHP Annual Meeting
Major NSAID Toxicity: Derivation and Internal Validation of a Simple Clinical Risk Score
Daniel Solomon¹, Ming Shao², Katherine E Wolski³, Steven E Nissen⁴, M. Elaine Husni⁵ and Nina Paynter⁶, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, ⁵Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ⁶Medicine, Harvard University, Boston, MA
Background/Purpose: NSAIDs and Coxibs represent one of the most commonly prescribed drugs by rheumatologists and are used regularly by >10 million Americans. While most patients…
Abstract Number: 2953 • 2018 ACR/ARHP Annual Meeting
Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
Debbie M. Boeters¹, Leonie E. Burgers¹, René E.M. Toes¹ and Annette H.M. van der Helm-van Mil^1,2, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Disease modifying antirheumatic drug (DMARD)-free sustained remission, the sustained absence of arthritis after cessation of all DMARD-therapy, is increasingly achievable with current treatment strategies.…
Abstract Number: 2954 • 2018 ACR/ARHP Annual Meeting
Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Angela Tong¹, Rishi J. Desai³ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: While efficacy of triple therapy [methotrexate (MTX), sulfasalazine (HCQ), and sulfasalazine (SSZ)] and TNF inhibitor (TNFi) plus MTX was similar in a previous clinical…
Abstract Number: 2955 • 2018 ACR/ARHP Annual Meeting
Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry
Lene Dreyer¹, Tine Iskov Kopp², Rikke Kart Jacobsen³, Melinda Magyari², Else Helene Ibfelt³, Henning Locht⁴, Finn Thorup Sellebjerg², Dorte Vendelbo Jensen⁵ and René Cordtz⁶, ¹Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ²Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁴Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ⁵The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Gentofte-Rigshospitalet, Hellerup, Denmark
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) have successfully been used for the treatment of immune-mediated inflammatory disorders including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 2956 • 2018 ACR/ARHP Annual Meeting
Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period
Meghna Jani, Belay Birlie Yimer, Therese Sheppard, Mark Lunt and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: The opioid epidemic in the U.S. has led to similar concerns about prescribed opioids in the U.K. In new users, the rate of escalation…
Abstract Number: 2957 • 2018 ACR/ARHP Annual Meeting
Socioeconomic Differences in Opioid Use By People with Inflammatory Arthritis
Ashley Fletcher^1,2, Marissa Lassere³, Rachel Black^4,5, Claire Barrett⁶, Graeme Carroll⁷, Susan Lester^8,9, Bethan Richards³, Lyn March¹⁰, Rachelle Buchbinder^11,12 and Catherine Hill^5,13,14, ¹Monash Department of Clinical Epidemiology, Cabrini Institute, Melbourne, Australia, ²Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³University of New South Wales, Sydney, Australia, ⁴Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁵Medicine, The University of Adelaide, Adelaide, Australia, ⁶Redcliffe Hospital, University of Queensland, Redcliffe, Australia, ⁷Adult Rheumatology and Osteoarthritis, University of Notre Dame, Mount Lawley WA, Australia, ⁸Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ⁹Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ¹⁰Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹¹Cabrini Institute, Victoria, Australia, ¹²Monash University, Melbourne, Australia, ¹³The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁴Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Internationally, prescription opioid use is often higher among patients of lower socioeconomic status (SES). In addition, despite improved treatments for inflammatory arthritis, opioid use…
Abstract Number: 2958 • 2018 ACR/ARHP Annual Meeting
Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
Ishita Aggarwal¹, Laura Trupin², Jing Li³, Lisa Gaynon⁴, Nancy Liu⁵, Chris Schlechter⁶, Louise Murphy⁷, Maria Dall'Era⁶ and Jinoos Yazdany⁶, ¹University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, UC San Francisco, San Francisco, CA, ⁴Internal Medicine, California Pacific Medical Center, San Francisco, CA, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, San Francisco, CA, ⁷Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Lupus nephritis (LN), seen in up to 60% of individuals with SLE, progresses to end stage renal failure in 10-30% of patients within 15…
Abstract Number: 2959 • 2018 ACR/ARHP Annual Meeting
Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Candace H. Feldman¹, Cameron Speyer¹, Rachel Ashby², Bonnie L. Bermas³, Shamik Bhattacharyya⁴, Eliza Chakravarty⁵, Brendan Everett⁶, Elizabeth Ferucci⁷, Aimee O. Hersh⁸, Francisco Marty⁹, Joseph F. Merola¹⁰, Rosalind Ramsey-Goldman¹¹, Brad Rovin¹², Mary Beth Son¹³, Laura Tarter¹⁴, Sushrut Waikar¹⁵, Jinoos Yazdany¹⁶, Joel Weissman¹⁷ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, UT Southwestern, Dallas, TX, ⁴Neurology, Brigham and Women's Hospital, Boston, MA, ⁵Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Cardiology, Brigham and Women's Hospital, Boston, MA, ⁷Alaska Native Medical Center, Anchorage, AK, ⁸Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁹Infectious Disease, Brigham and Women's Hospital, Boston, MA, ¹⁰Medicine, Rheumatology and Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Ohio State University Wexner Medical Center, Columbus, OH, ¹³Boston Children's Hospital, Harvard Medical School, Brookline, MA, ¹⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁵Renal, Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, San Francisco, San Francisco, CA, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The U.S. Agency for Healthcare Research and Quality developed a set of general ambulatory care-sensitive conditions that may result acute care use (hospitalizations and…
Abstract Number: 2960 • 2018 ACR/ARHP Annual Meeting
Evaluation of Performance Measures Reveals Delays and Sub-Optimal Access to Rheumatology Care and Treatment
Claire Barber¹, Diane Lacaille², Peter Faris³, Dianne P. Mosher⁴, Steven J. Katz⁵, Joanne Homik⁶, Jatin Patel⁷, Sharon Zhang⁷, Cheryl Barnabe⁸, Glen Hazlewood⁹, Vandana Ahluwalia¹⁰, Natalie J. Shiff¹¹, Vivian P. Bykerk¹², Marinka Twilt¹³, Susanne Benseler¹⁴, Jennifer Burt¹⁵ and Deborah A. Marshall¹⁶, ¹Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Arthritis Research Canada/University of British Columbia, Medicine/Rheumatology, Richmond, BC, Canada, ³Alberta Health Services, Alberta, AB, Canada, ⁴Med, University of Calgary, Calgary, AB, Canada, ⁵Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Alberta Health Services, Calgary, AB, Canada, ⁸Medicine, University of Calgary, Calgary, AB, Canada, ⁹Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, ¹⁰William Osler Health Center, Brampton, ON, Canada, ¹¹University of Florida, Gainesville, FL, ¹²Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ¹³University of Calgary, Calgary, AB, Canada, ¹⁴Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ¹⁵St. Clare's Mercy Hospital, Eastern Health, St. John's, NF, Canada, ¹⁶Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Early diagnosis, treatment and ongoing care are critical to optimize RA outcomes. The purpose of the study was to evaluate key elements of RA…
Abstract Number: 2961 • 2018 ACR/ARHP Annual Meeting
Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Providers from 2010 to 2018
Kiana Johnson¹, Cuoghi Edens², Peter Chira³, Aimee O. Hersh⁴, Y. Ingrid Goh⁵, Joyce Hui-Yuen⁶, Rebecca E. Sadun⁷, Nora G. Singer⁸, Lynn R. Spiegel⁹, Jennifer N. Stinson¹⁰, Patience H. White¹¹ and Erica Lawson¹², ¹Department of Pediatrics, East Tennessee State University, Johnson City, TN, ²Division of Pediatric Infectious Diseases and Rheumatology and Division of Rheumatology, Rainbow Babies and Children's Hospital and University Hospitals Cleveland Medical Center, Cleveland, OH, ³Pediatric Rheumatology, Rady Children's Specialists of San Diego, San Diego, CA, ⁴Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁵Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Cohen Children's Medical Center, New Hyde Park, NY, ⁷Adult and Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁸Departments of Medicine and Pediatrics, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH, Cleveland, OH, ⁹Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Department of Medicine, Division of Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ¹²Pediatrics/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Healthcare transition is the “purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented health care…
Abstract Number: 2962 • 2018 ACR/ARHP Annual Meeting
Diagnostic Accuracy of Gout in Electronic Health Records and the Role of Rheumatology Electronic Consults
Juliana Chang¹ and Maida Wong², ¹Internal Medicine, University of California, Irvine, School of Medicine, Orange, CA, ²Rheumatology, Tibor Rubin VA Medical Center, Orange, CA
Background/Purpose: Gout is the most prevalent inflammatory arthritis globally. Despite treatment advances, it still has a significant effect on quality of life and healthcare costs.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].